Overview

Minagene’s HRR gene testing utilizes tumor and germline matched comprehensive genomic profiling to screen for mutations in homologous recombination repair genes (BRCA1, BRCA2, PALB2, etc.).

Methodology

Tissue specimens undergo nucleic acid extraction and library preparation for hybrid capture-based next generation sequencing of all clinically actionable exons/introns across 45+ key HRR genes. Proprietary bioinformatics analyze both somatic and constitutional alterations to determine eligibility for PARP and other targeted therapies.

Key Highlights of Minagene’s Homologous Recombination Repair Gene Testing

-Identifies defective HRR signature regardless of cancer type

-Determines germline/somatic origin of pathogenic variants

-Assesses complex genomic profiles for synthetic lethality

-Supports treatment with PARP inhibitors, platinum agents

-Improves outcomes through precision therapy selection

By using an unbiased multi-gene approach, Minagene’s solution comprehensively interrogates the HRR pathway. Matched tumor-normal analysis guides definitive targeted therapy and enrollment in investigative clinical trials.

Physicians should order HRR testing for advanced solid tumors refractory to standard therapies, particularly ovarian and breast cancers evaluated for PARP inhibitors.